Physician profile
Michael S Kaplan
NPI 1841298593
$611,828.37
in general payments reported to CMS, 2019-2025
16 companies · $134K in 2025
The $134K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127K · 2020: $70K · 2021: $70K · 2022: $81K · 2023: $46K · 2024: $84K · 2025: $134K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $234K · Travel and Lodging: $16K · Food and Beverage: $8,788 · Consulting Fee: $4,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $233,945.14 |
| Travel and Lodging | $16,241.27 |
| Food and Beverage | $8,788.46 |
| Consulting Fee | $4,775.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $487,247.67 | 2019-2025 | Wegovy, Saxenda |
| Lilly USA, LLC | $115,294.89 | 2019-2025 | Zepbound, Taltz, Mounjaro |
| Amgen INC. | $7,143.77 | 2019 | |
| Novo Nordisk As | $1,050.00 | 2022 | |
| Intra-Sana Laboratories | $251.01 | 2022-2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Currax Pharmaceuticals LLC | $218.60 | 2019-2025 | Contrave, Nexlizet, Nexletol |
| Vivus LLC | $184.53 | 2019-2024 | Qsymia |
| Boston Scientific Corporation | $148.24 | 2025 | General - Vascular Intervention |
| Eisai INC. | $129.00 | 2019 | |
| Corcept Therapeutics | $36.44 | 2025 | Korlym |
| Sobi, INC | $29.58 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.71 | 2021 | |
| Ardelyx, INC. | $21.49 | 2025 | Ibsrela |
| Nalpropion Pharmaceuticals LLC | $19.20 | 2019 | |
| Horizon Therapeutics Plc | $16.89 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $12.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.